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1. Scope and Preface 
The Advisory Council on the Misuse of Drugs (ACMD) is a Non-Departmental Public 
Body (NDPB) that has a statutory duty to advise, and to consider any matter referred 
to them by ministers, on drug related issues in the UK; on their control, classification 
and scheduling under the Misuse of Drugs Act 1971 and its Regulations.  
 
To set this report in context, the drugs landscape is rapidly changing in light of the 
well reported increased use of new psychoactive substances (‘legal highs’). It is a 
continuing challenge to consider the harms of new psychoactive substances, 
particularly when the evidence base concerning their harms is not as well developed 
as that of many long standing drugs of misuse.  
 
The purpose of the work in this report is to improve the framework for providing 
advice to ministers on the harms of drugs. The ACMD considered that this work 
would not seek to update or revisit the present classification system of drugs, but 
would serve as a tool to augment the ACMD’s deliberations and judgements in this 
challenging field.  
 
In this report the ACMD considered the use of Multi-Criteria Decision Analysis 
(MCDA) to support the process of developing a framework. MCDA is often used in 
such situations where decision makers need to derive a transparent outcome, but in 
an environment where there may be many and sometimes conflicting evaluations. 
The technique of MCDA aims to address these conflicts and derive a compromise. 
The process is based on developing a list of criteria and, using evidence, formulating 
judgements and then preferences to derive an outcome. The process is therefore 
subjective and different users of the model may derive different outcomes on the 
same evidence dependent on their preferences (although the importance of different 
preferences can be tested through sensitivity analyses). However, using MCDA 
increases transparency by allowing others to see the process by which decisions 
have been derived. The key part to the model is the development of criteria that 
express the ways in which substances can be harmful, which comprise of physical, 
psychological and social harms.  
 
By publishing this methodological report the ACMD consider it will provide the 
opportunity for individuals and organisations to consider the criteria and to refine this 
approach in the future.   
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2. Executive Summary  
 
The ACMD has explored the use of a multi-criteria decision analysis (MCDA) model 
for evaluating drug harms. The model provides a conceptual framework for further 
consideration and refinement. This approach could provide a basis for exploring and 
formulating recommendations to ministers as part of the structure of ACMD reports. 
The ACMD recognises that further and on-going development of the model is 
necessary, particularly as society and drugs of misuse change. The model presented 
should be considered as illustrative rather than absolute. 
 
The ACMD developed 16 criteria that express the ways in which substances can be 
harmful, which comprised physical, psychological and social harms. Each criterion 
was carefully defined and assigned an agreed weighting to enable drugs to be 
meaningfully evaluated. 
 
Using the model requires evidence to evaluate the harms of a substance against 
each criterion and subsequently judgements to be made on the relative importance 
of the criteria. For example, whilst there can be robust scientific evidence of the harm 
caused by a substance, there is no evidential basis that will indicate whether ‘drug-
related crime’ is more or less important than ‘drug-related mortality’. The latter are 
value judgements which will depend on an individual’s standpoint and the purposes 
for which the model is being used (e.g. value judgements will change if the model is 
being used to determine the allocation of economic resources, compared to 
developing a legal framework).  
 
The report describes the model and how it may be used in a decision making 
context. 
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3. Introduction  
 
This report presents a method for considering the relative harms of substances using 
a Multi Criteria Decision Analysis (MCDA) model. The Advisory Council on the 
Misuse of Drugs (ACMD) held two meetings on 23 - 24 March 2009 and on 19 June 
2009 to develop an initial model for appraising and evaluating drug harms and the 
model was considered further at subsequent ACMD meetings. 
 
The decision conferencing format (Philips, 2007) that was adopted for developing the 
model provided a structure for deliberative discourse (Renn, 1999) among ACMD 
members, enabling them to challenge shared assumptions and develop new 
perspectives. 
 
A list of current ACMD members is provided in Appendix 1.  
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4. MCDA Methodology 
 
Comparators 
In order to develop the MCDA model the ACMD defined 1) a range of criteria 
covering the harms that characterise the drugs under consideration, and 2) an initial 
set of evaluations and weighting for each criterion.  
 
To develop the structure of the model the ACMD discussed the substances that 
would need to be sufficiently discriminated by the model. Proof of concept for the 
model was piloted using representative inputs for a number of drugs. However, it 
was decided not to take this preliminary test any further at this stage as objective 
evidence from, for example, intelligence and scientific literature was not available for 
these across all the criteria.  
 
Criteria 
Sixteen criteria were developed to assess the harms of drugs. Nine criteria fell under 
the heading of harms to the user and the remaining seven under harms to others.  
These were further divided between physical, psychological and social harms.  A 
value-tree representation of the criteria and their clusters is shown in Figure 11. 
 
The tree shows objectives at the nodes, and criteria against which the drugs are to 
be evaluated at the extreme right (definitions are provided in Table 1). Thus, the 
main objective is to determine an ordering of the drugs at the OVERALL HARM 
node. The next level to the right provides separate orderings TO USERS (harm to 
those who are using the drug) and TO OTHERS (harm as a consequence of the use 
of drugs to others both directly and indirectly).  Each of these is broken down 
according to the PHYSICAL, PSYCHOLOGICAL and SOCIAL orderings.   
 
To assess the harm of any individual substance (or group of substances) evidence 
for the degree of harms would be required for each of the criteria at the extreme right 
of the value tree. 
 
 
 
                                                 
1 The value tree and all subsequent aspects of the model were implemented in Hiview 3, a computer 
program originally developed at the London School of Economics.  It is available from the current 
developers, Catalyze Limited, at www.catalyze.co.uk. 
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Figure 1. The evaluation criteria organised by harms to users and harms to 
others, and clustered under physical, psychological and social effects.2 
 
 
                                                 
2 See Table 1 for full criteria titles.  
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Table 1: Definitions of the evaluation criteria.   
Short Name Description 
 HARM TO USER: 
DRUG SPECIFIC 
MORTALITY 
Intrinsic lethality of the drug expressed as ratio of lethal dose and standard dose 
(for adults). 
100 = an inverted ratio of 33% (ratio of 3 --> 1/3) 
50 = an inverted ratio of 10% (ratio of 10 --> 1/10) 
0 = an inverted ratio of 0%  
DRUG RELATED 
MORTALITY 
The extent to which life is shortened by the use of this drug (excludes drug 
specific mortality), e.g. road traffic accidents, lung cancers, blood borne viruses 
(BBV), suicide. 
DRUG SPECIFIC 
DAMAGE 
Drug specific damage to physical health, e.g. cirrhosis, seizures, strokes, 
cardiomyopathy, stomach ulcers. 
DRUG RELATED 
DAMAGE 
Drug related damage to physical health, including consequences of e.g. unwanted 
sexual activities and self-harm, BBV, emphysema, damage from cutting agents. 
DEPENDENCE The extent to which this drug creates a propensity or urge to continue to use 
despite adverse consequences (ICD10 or DSM4). 
SPECIFIC IMPAIRMENT 
FUNCTION 
Drug specific impairment of mental functioning, e.g. amphetamine induced 
psychosis, intoxication. 
RELATIVE IMPAIRMENT 
FUNCTION 
Drug related impairment of mental functioning, e.g. mood disorders secondary to 
drug-users lifestyle or drug use. 
LOSS OF 
TANGIBLES  
Loss of tangible things, e.g., income, housing, job, educational achievements, 
criminal record, imprisonment.  
LOSS OF 
RELATIONSHIPS Loss of relationship with family and friends. 
 HARM TO OTHERS: 
INJURY The extent to which this drug increases the chance of injuries to others both 
directly and indirectly, e.g. violence (including domestic violence), traffic accident, 
foetal harm, drug waste, secondary transmission of BBV. 
CRIME The extent to which the use of this drug involves or leads to an increase in volume 
of acquisitive crime (beyond the possession or supply of the drug) directly or 
indirectly (at the population level, not the individual) 
100 = the most harmful (on a relative scale), 0 = no harm. 
ENVIRONMENTAL 
DAMAGE 
The extent to which the use and production of this drug causes environmental 
damage locally, e.g. toxic waste from amphetamine factories, discarded needles. 
FAMILY ADVERSITIES The extent to which the use of this drug causes family adversities, e.g. family 
breakdown, economic well-being, emotional well-being, future prospects of 
children, child neglect. 
INTERNATIONAL 
DAMAGE 
The extent to which the use of this drug causes damage at an international level, 
e.g. deforestation, destabilisation of countries, international crime and new 
markets. 
ECONOMIC COST The extent to which the use of this drug causes direct costs to the Country (e.g. 
healthcare, police, prisons, social services, customs, insurance, crime) and 
indirect cost (e.g. loss of productivity, absenteeism). 
COMMUNITY The extent to which the use of this drug creates decline in social cohesion and 
decline in the reputation of the community. 
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To be useful and satisfy the theoretical requirements of MCDA, criteria are subject to 
certain constraints, which ensure that the calculated weighted averages are 
meaningful. The requirements are that the criteria should be: (1) complete in 
covering all the important aspects of harm (2) non-redundant in that they distinguish 
between drugs and do not include any unnecessary criteria (3) operational so the 
options can be judged against the criteria as more or less preferred (4) mutually 
preference independent so that in scoring the drugs on one criterion it is not 
necessary to know the scores on any other criterion (5) unique, so there is no 
double-counting (6) requisite number, neither too many criteria nor too few, and (6) 
accommodating of performance over time (Belton et al, 2002). With input from the 
facilitators these constraints were met. 
 
Assessing drugs 
For each criterion a given drug would be scored using points out of 100, with 100 
assigned to the most harmful drug on the criterion and zero meaning ‘no harm’. 
Weighting subsequently compares the drugs scored 100 across all the criteria, 
thereby expressing the judgement that those drugs scored 100 are more harmful 
than others.   
 
In scaling the drugs, care is required to ensure that each successive point on the 
scale represents equal increments of harm. Thus, if a drug is scored 50 for a 
particular criterion, then it should be half as harmful as the drug scored 100 on that 
criterion. Because zero represents no harm, this scale can be considered a ratio 
scale, which facilitates interpretation of combined scales. 
 
The proposed scale for drug specific mortality is defined in terms of the ratio of a 
lethal dose to a standard dose, which leads to no upper limit for drugs that are not 
lethal. However, by inverting the ratio, this problem is overcome, as shown in the first 
row of Table 1: a score of 0 is given to the new ratio of zero, a score of 50 to a ratio 
of 1/10, and a score of 100 to a ratio of 1/3. However, this is clearly a non-linear 
scale, and might be the subject of further consideration.   
 
The scores derived from this part of the process are the first set of value judgements 
that are expressed in MCDA. Even if harm is measured objectively, it would still be 
necessary to convert the metric into a preference value scale, indicating how harm is 
a function of the measured quantity, called a ‘value function’ in MCDA.  For example, 
using the first criterion, doubling the metric might be interpreted as quadrupling the 
harm.  That non-linear relationship is evident in the definition given here.  Doubling 
the score from 5 to 10 implies that harm increases from 1/10 to 1/3, a ratio of 3.33 to 
1.  Alternatively, the difference between 10 and 5, 1/3 – 1/10, compared to the 
difference between 5 and 0, 1/10 – 0, is in the ratio of 2.33 to 1.  Either way, harm 
increases more from 5 to 10 than it does from 0 to 5.  This is clearly a value 
judgement.  
 
Consistency checking is an essential part of proper scoring, as it helps to minimise 
bias in the scores, and encourages realism in scoring. It is important that the 
underpinning evidence is considered as scores can, and should, change according 
to changes in the evidence. In addition, it is important to look at the relativities of the 
scores, within a given criterion, to see if they, relatively, are right. 
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Swing weighting 
Once scored, the criteria are weighted. The purpose of weighting is to ensure that 
the units of harm on the different preference scales can be compared and combined 
across criteria. To ensure that assessed weights are meaningful, swing weighting is 
used. Some criteria are more important expressions of harm than others. Although 
that is an intuitively appealing statement, more precision is needed to enable the 
assessment of weights to the criteria. This is accomplished with the concept of 
‘swing weighting’. As an analogy, both Fahrenheit and Celsius scales contain 0 to 
100 portions, but the swing in temperature from 0 to 100 on the Fahrenheit scale is, 
of course, a smaller swing in temperature than 0 to 100 on a Celsius scale; it takes 5 
Celsius units to equal 9 Fahrenheit units. The purpose of weighting in MCDA is to 
ensure that the units of harm on the different preference scales are equivalent, thus 
enabling weighted scores to be compared and combined across the criteria.  
Weights are, in essence, scale factors. Thus, MCDA does not directly compare 
different kinds of harms, it compares the preference values associated with the 
harms. The common unit is preference value, just as money is the common unit in 
cost-benefit analysis. 
 
To assess these scale factors, the meaningful question to answer is this: “How much 
do you care about the added harm represented by a swing from a preference value 
of 0 to a preference value of 100 on this criterion compared to the 0-to-100 swing on 
another, specified, criterion?” It is the combination of the 0-to-100 difference in 
preference values, and how much the assessor cares about them that defines an 
increment in value. In MCDA, the scales that are compared are value scales, not 
harm scales. The distinction is important. On the one hand, harm expresses a level 
of damage. Value, on the other hand, indicates how much that level of damage 
matters in a particular context. And because context can affect assessments of 
value, it is likely that one set of criterion weights for a particular context may not be 
satisfactory for decision making in another context. 
   
It follows, then, that to judge the value of a drug’s harm, two steps in thinking must 
be separated. First, it is necessary to think about the added harm going from no 
harm at all to the level of harm represented by a score of 100. That is a 
straightforward assessment of a difference in harm, from no harm to the harm 
associated with the worst drug on that criterion. The next step is to think about how 
much that difference in harm matters in a given context.  “How big is the difference in 
harm and how much do you care about that difference?” This is the question that is 
posed in comparing the 0-to-100 swing in harm on one scale with the 0-to-100 swing 
on another scale. 
 
To start the process, one needs to assess the weights within each grouping of 
criteria, then across the groupings. For instance, in starting with the physical harm to 
users grouping, there are four criteria. Assessors would compare the swing in harm 
from those adjudged to be least harmful to most harmful in one criterion. This is done 
by first considering the differences in actual harm and second, judging how much 
that difference matters. Then, in a similar way the first swing would be compared to 
the swing on the third criterion and so on. As a result of paired-comparisons, an 
arbitrary swing weight of 100 can be assigned to the criterion adjudged most 
harmful. This is then continued at each first node of Figure 1.  
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The same process as above is then applied to assessing the relative weights for the 
three criteria under the psychological harm grouping, and assigning the biggest of 
the three swings a weight of 100.  It should be noted that assigning 100 to one scale 
in this grouping does not necessarily represent the same level of harm as the 100 in 
the previous grouping, just as 100 degrees Fahrenheit does not mean the same 
temperature as 100 degrees Celsius.  
 
In the next part of the process it is necessary for users to equate scales given 
weights of 100, one from each node.  First, the one criterion that was given a weight 
of 100 in each of the three groupings under TO USERS is considered and displayed 
for each of those three scales. The judgements of weight would now be more difficult 
to make as they require comparisons of physical, psychological and social harm. 
However, the group which users agree matters most retains the score of 100 on that 
scale, and the other 100-weighted criteria are then compared to that one. 
 
Finally, the single most harmful swings under TO USERS and under TO OTHERS 
would be compared, completing the weighting process.  At this point the units of 
harm on all scales would be equivalent, enabling the harm scores to be combined 
within any grouping simply by adding the weighted scores. 
 
To ensure that final results are displayed on a 0 to 100 scale, the Hiview programme 
normalises the weights at each node, retaining the ratios of weights to each other, 
but ensuring the normalised weights sum to one.  This normalisation process is 
carried out over the entire value tree; it does not, of course, have any influence on 
the relative results at any node, or on the final overall ordering. 
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5. Results 
Overall 
With scoring completed accurately and weighting determined it would be possible to 
calculate sums of weighted scores and show results at any node. One way to do this 
is to display the overall weighted score of each drug as a bar graph. Stacked bar 
graphs could show the contribution of harm to users and harm to others in different 
colours, or could show the extent to which each criterion contributes to the overall 
result for each drug. 
 
Results can also be separated out in an X-Y plot to show, for example, harm to users 
on one axis and harm to others on the other axis so the relative contributions of 
those types of harm can be considered independently of the relative weights on 
those two types of harm. 
Sensitivity Analyses 
These analyses explore the sensitivity of the overall results to changes in weights on 
the criteria. This is where different options can be explored, for instance, some users 
of the model may make different judgements on the weightings depending on their 
objectives for using the model. This is important to explore as it provides 
transparency to the value judgements that any group may place on each of the 
criteria in the overall assessment of relative harm.   
 
Sensitivity analyses can also be conducted at nodes, showing the overall results as 
the weight on the node is changed.   
Comparative Analyses 
Comparative analyses can be used to explore, for example, why a drug is judged to 
be most harmful on a criterion-by-criterion basis. This can be viewed as a relative 
contribution to the overall harm score, a different kind of display from the stacked bar 
graph. An instructive comparative analysis compares any drug with any other drug, 
which highlights with a simple graphical display the important ways in which one 
drug differs in its harm from another drug. 
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6. Discussion and Conclusion 
 
The model that the ACMD explored in this paper looks to demonstrate a proof of 
concept of the use of such frameworks in the decision making process. The model 
provides a conceptual, structured framework for the consideration of the harm of a 
given drug.  
 
The model is, necessarily, a draft and has not yet had the external scrutiny required 
for the development of rigour; full validation of the model is required to test its 
underlying assumptions. This process would include the input of datasets and the 
gathering of evidence that is needed to underpin the judgements and preferences. 
However, the model is presented as a potential tool for developing contributions to 
the decision making process that are credible and consistent.   
 
The approach presented facilitates a transparent and consistent method for 
considering the evidence and the gaps for new drugs of use. The framework builds 
on the work of Nutt et al (2007) and the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA, 2009) by providing a more complete set of criteria, a 
scoring system that is more sensitive to differences than the rating scales typical of 
non-MCDA-based approaches, and a method for weighting criteria according to their 
relative importance (or ‘preference’).  
 
Using such a model has the advantages of being able to consider all the harms of a 
substance objectively and comparably with others, enables harms to be weighted 
according ‘values’, and being able to compare a drug that is very harmful but rarely 
used to a less harmful drug used by many, which has been a particular challenge to 
the ACMD in recent years. The model is developed so that the degree of individual 
harm is considered in the criteria under TO USERS, while many of the criteria under 
TO OTHERS accommodate the numbers of users harmed. 
 
A number of issues arose in the ACMD’s consideration of employing the model in the 
development of its advice. For example, unequivocal data about substances on all 
the 16 criteria will never be wholly adequate. Thus, there is further discussion to be 
had about how to manage the model when there is insufficient evidence to score 
some of the criteria. Structured expert judgement will always be required in such 
cases, which can be supported by sensitivity analysis of the model’s outputs. This is 
currently very topical given the current rise in prevalence of new synthetic 
psychoactive substances (e.g. those substances known as ‘legal highs’) and the 
paucity of data available.  
 
Further refinement could also be made to the criteria; particularly clarification should 
be given for whether a substance is assessed from a ‘user’ or ‘abuser’ perspective 
as this could significantly effect the scoring of some of the criteria. For example, 
some users of a substance, may manage their use in a way that causes minimal 
harm to themselves and others, whereas others may abuse the substance such that 
their use causes significant harm to themselves and others. The tendency of a 
substance to lead to abuse is included in the model through the criterion of 
dependency.   
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The model has not been developed to take into account an assessment of ‘poly-drug 
use3’ and the consequent increased potential for harm. This is currently an area of 
consideration by the ACMD, but how it might be incorporated into the model needs 
further consideration. 
 
The ACMD recognise that further development is required of the model, in particular: 
the implementation of the model’s criteria to improve the validity of input data; the 
development of value functions to convert the metrics into preference values; and 
the exploration of how different contexts (e.g. investment decisions, public health 
campaigns, law enforcement) and constituencies who might weight the criteria 
differently. 
 
The ultimate purpose of a fully developed model would be to seek to improve the 
transparency of policy recommendations for decision makers in the drugs field and to 
facilitate communication with the public. Such a model would allow adviserrs to 
explore considerations for policy recommendations and provide a mechanism for 
examining how different public perceptions of risks associated with psychoactive 
substances could affect policy-making.  Sensitivity analyses provide the means to 
see how the relative ranking of harm might change under different scenarios, 
enabling advisors and decision makers to develop strategies that would be robust to 
these different perceptions. 
 
Although the MCDA model remains largely subjective, it offers a framework on the 
harms associated with substances rather than providing definitive answers. It may be 
that it provides a mechanism for combining many sources of information, along with 
their expert judgements, in such a way that the very best independent expert advice 
can be formulated expeditiously in response to new information and changing social 
conditions. 
 
The ACMD recognises the need for further, external, development of the model and 
for research that can test the underlying assumptions. The ACMD welcomes such 
further research on this initial study to consider the next steps on how best to employ 
such tools in the context of providing advice.   
 
                                                 
3 Poly-drug use’ is considered to be the simultaneous use of more than one drug. 
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